Dihexa

Three distinctions stand out. First, mechanism: Dihexa works through the HGF/c-Met receptor tyrosine kinase system, a completely different molecular pathway than Semax (melanocortin receptors) or Selank (GABA-B and tuftsin receptors). This means it can theoretically be combined with either without receptor competition. Second, bioavailability: as a peptidomimetic rather than a true peptide, Dihexa is orally and transdermally active in rodents — Semax and Selank require intranasal or injectable delivery. Third, and critically, evidence stage: Semax and Selank have published randomized controlled trials in humans from Russian clinical programs. Dihexa has no published human clinical data whatsoever. This last distinction is the most important when evaluating risk.

This claim refers to a specific in vitro measurement in hippocampal neuron culture synaptogenesis assays — not to cognitive effects in living subjects. In that specific experimental context, Dihexa series compounds produced statistically significant synaptogenesis at femtomolar concentrations (10⁻¹⁵ M), while BDNF required nanomolar concentrations (10⁻⁹ M) to produce equivalent effects. The ratio of those concentrations is approximately 10⁶ to 10⁷, depending on the specific assay conditions — hence the claim.

What the claim does not mean: that Dihexa produces 10 million times stronger cognitive effects in humans, or that 10 million times less Dihexa is needed for human benefit compared to any BDNF-activating compound. In vitro potency and clinical efficacy are different things. The appropriate interpretation is that Dihexa activates synaptogenesis signaling at extraordinarily low concentrations in a cell culture system, which is scientifically significant but requires human validation to be clinically meaningful.

No. There is no human evidence that Dihexa treats Alzheimer's disease or any other neurodegenerative condition. The preclinical data (aged rat spatial learning improvement) is relevant to the hypothesis that Dihexa could target age-related synapse loss — which is a feature of Alzheimer's pathology — but aged rat spatial learning models are not validated predictors of Alzheimer's treatment efficacy. Many compounds that improved aged rat cognition failed in human Alzheimer's trials (most famously: dozens of HDAC inhibitors, secretase inhibitors, and amyloid-targeting compounds).

The honest answer is that the preclinical findings justify the design and execution of a human Phase I safety trial, which has apparently not yet occurred. Without that, any claim about Dihexa treating Alzheimer's is speculation far outrunning the evidence.

Angiotensin IV (AngIV) is the hexapeptide Val-Tyr-Ile-His-Pro-Phe, derived from angiotensin II by sequential aminopeptidase cleavage. It was known to have CNS cognitive effects in rodents (improved memory consolidation, object recognition) but suffered from two pharmacological problems: poor BBB penetration and rapid enzymatic degradation. The Harding laboratory used AngIV as a starting scaffold and developed peptidomimetics that retained the pharmacophore responsible for HGF/c-Met potentiation while eliminating the structural features responsible for metabolic instability and poor CNS penetrance. Dihexa is the result of that optimization — sharing the Tyr-Ile dipeptide core pharmacophore with AngIV but modified at both termini to create a stable, BBB-penetrant, orally bioavailable compound.

The safety profile of Dihexa in humans is unknown. Rodent studies at research doses did not identify acute toxicity signals, and no adverse histopathological findings in brain or systemic organs were reported in the available published literature. However, the c-Met signaling pathway that Dihexa potentiates has been implicated in oncogenesis — c-Met amplification and gain-of-function mutations are found in multiple cancers (gastric, lung, liver, renal). Whether chronic HGF/c-Met potentiation at therapeutic CNS doses could promote tumorigenesis is an entirely open question that has not been investigated in available published studies. This concern does not mean Dihexa is carcinogenic — it means the question has not been answered. Standard oncology biomarkers (CEA, PSA, AFP depending on cancer risk profile) as well as monitoring for unexplained mass lesions would be a minimum safety approach in any supervised research protocol.

The reasons are not publicly documented, but several factors typically explain the preclinical-to-clinical gap: (1) Funding — Phase I human trials cost $1–5M minimum; academic labs rarely have this without industry partnership or NIH grants specifically for IND-enabling studies. (2) Intellectual property — without a strong patent position, industry funders may not be interested. (3) Regulatory pathway — cognitive enhancement does not have a clear FDA regulatory pathway the way disease treatment does; a cognitive decline indication requires demonstrating efficacy in a diagnosed patient population. (4) The c-Met oncogenesis concern discussed above may have created regulatory caution. The lack of human trials reflects these practical barriers, not necessarily a judgment that the science is flawed. The preclinical data from the Harding group remains scientifically legitimate.